Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 9/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786868 | 0.94 | CXCR4 (0.54) | KMT2ACXCR3KCNA5TSHRMEN1 | |
| SCHEMBL4913474 | 0.89 | ALDH1A1 (0.55) | KMT2ACXCR3TSHRMEN1ALDH1A1 | |
| SCHEMBL4922749 | 0.84 | CXCR3 (0.47) | KMT2ACXCR3KCNA5CXCR4ALDH1A1 | |
| SCHEMBL4926200 | 0.82 | KCNA5 (0.45) | KMT2ACXCR3KCNA5TSHRMEN1 | |
| SCHEMBL4922150 | 0.81 | CXCR4 (0.49) | CXCR4SMN1; SMN2 | |
| SCHEMBL4922140 | 0.81 | CXCR4 (0.49) | CXCR4SMN1; SMN2 | |
| SCHEMBL4924546 | 0.79 | CXCR3 (0.64) | KMT2ACXCR3KCNA5TSHRMEN1 | |
| SCHEMBL4921023 | 0.79 | CXCR4 (0.50) | KMT2AMEN1CXCR4SMN1; SMN2NPSR1 | |
| SCHEMBL4926248 | 0.78 | SMN1; SMN2 (0.43) | KMT2AMEN1CXCR4ALDH1A1LMNA | |
| SCHEMBL14025440 | 0.77 | ALDH1A1 (0.56) | KMT2ATSHRMEN1CXCR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | KMT2A 682/4885CXCR3 248/4885KCNA5 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.